Overview

UBT251 Injection Phase II Study (Overweight or Obesity)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Phase:
PHASE2
Details
Lead Sponsor:
The United Bio-Technology (Hengqin) Co., Ltd.